Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

A Web-based software toolkit for accessible and best-practice machine learning analyses in biomedical research

Created on 08 Jun 2026

Authors

Morais Lyra Junior, P. C., Qiu, J., Van Dang, K., Pybus, A., Narvaez-Bandera, I., Singh, M. A., Gu, Q., Sargent, L., Creason, A. L., Goecks, J.

Abstract

Machine learning is increasingly central to biomedical research, but using machine learning well often requires substantial computational expertise and methodological care to produce high-quality results. To make machinelearning tools more accessible to biomedical researchers while supporting best-practice approaches, we developed the Galaxy Learning and Modeling (GLEAM) software toolkit. GLEAM enables researchers to performsupervised machine learning analyses through a set of web-based, code-free software tools for tabular, image, and multimodal biomedical datasets. GLEAM standardizes data partitioning, model selection, training, evaluation,and reporting, helping researchers apply machine learning with greater rigor and consistency. GLEAM runs on the Galaxy computational workbench and uses Galaxy's core features to make all analyses accessible,reproducible, and scalable. We validated GLEAM on three biomedical tasks: predicting patient response to immunotherapy, skin lesion classification, and cancer recurrence prediction. Across these tasks, GLEAM producedhighly accurate predictive models and improved transparency, reproducibility, and rigor.

Preprint server: bioRxiv
The authors list and abstract were imported from bioRxiv on 08 Jun 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this preprint? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement